Mass spectrometric investigation of the DNA-binding properties of an anthracycline with two trisaccharide chains
the methyl group in the side chain of Dn is hydroxylated in Dx. This difference has a significant effect on the anti-cancer activities of these two compounds: Dn is used in chemotherapy against acute lymphoblastic or myeloblastic leukemias, while Dx is an essential element used in the treatment of breast cancer, childhood solid tumours, soft tissue sarcomas and aggressive lymphomas [1, 2] .
While these compounds have been used as an important part of chemotherapeutic regimens for more than 30 years, their mode(s) of action remain unclear [1] . The binding of anthracyclines to DNA (in vitro) has been extensively investigated using a range of biochemical and biophysical techniques, including equilibrium dialysis, fluorescence spectroscopy, observation of the melting temperature (T m ) of DNA and Dnase I footprinting analysis [3] [4] [5] [6] [7] . X-ray crystal structures of anthracyclines show that the planar ring systems of anthracyclines intercalate between base pairs of double-stranded (ds) DNA and that the sugar(s) lie in the minor groove [8, 9] . Flow cytometry experiments have shown that anthracyclines accumulate in cell nuclei and bind to DNA [10] . The binding to nuclear DNA is expected to cause inhibition of replication and transcription supporting that the intercalation into DNA is an important mechanism in the activity against cancer cells. The structures of the anthracyclines allow for many interactions with other cellular components and macromolecules and other mechanisms for their anti-cancer activity include: (i) generation of free radicals that may damage DNA, lipids and proteins, (ii) alkylation of DNA, (iii) DNA cross-linking, (iv) interference with activities of enzymes that unwind DNA such as helicases, (v) direct membrane effects, (vi) DNA damage caused by inhibition of topoisomerase II, and (vii) induction of apoptosis in response to topoisomerase II inhibition [1, 11] . The most widely accepted mode of action of the anthracyclines involves intercalation into DNA resulting in stabilization of a transient reaction intermediate of topoisomerase II activity in which DNA strands are cleaved and covalently linked to tyrosine residues of the enzyme [1] .
The mechanisms outlined above are not exclusive of each other, and there are numerous overlapping cellular processes that can be affected. Given the complexity of the effects of anthracyclines in the cell, it is perhaps not surprising that there are no clear definitions of structural features that confer a specific biochemical or clinical effect. Further, this complexity contributes to difficulties in predicting the onset and severity of the negative aspects of anthracycline chemotherapy such as the development of resistance by tumour cells and cardiotoxicity [1] . Other than Dn and Dx, anthracyclines that have been used in the clinic include epirubicin (where the C-4′ hydroxyl of the daunosamine sugar in Dx is equatorial rather than axial), idarubicin (where the methoxy group at C-4 of the Dn aglycone is lacking), pirarubicin (which is a 4-tetrahydropyranol Dx) and aclacinomycin A (aclarubicin, where there are changes to the aglycone and there is a trisaccharide attached to C-7, see Figure 1 ). Idarubicin has a broader spectrum of activity than Dn that is thought to be related to increased cellular uptake (as a result of greater lipophilicity) and enhanced stabilization of the ternary drug-DNA-topoisomerase II complex [12, 13] . Pirarubicin and aclacinomycin A show modest improvements against development of drug resistance compared with Dx and Dn [14] .
There are numerous crystal structures of anthracycline-DNA complexes. The sugar residue is important in forming the stable ternary complex with topoisomerase II, and the sequence selectivity of anthracycline-stimulated DNA cleavage is influenced by the substituents at the C-3′ (primary amine in Dx and Dn) [13] . Furthermore, anthracyclines containing disaccharides such as the Dx derivative, MEN10755, have been shown to have activity against different cancers, and this compound is active against Dx-resistant tumours [15, 9] . In order to produce anthracyclines with different pharmacological profiles, clinical efficacy and diminished side effects, a range of strategies has been employed to alter the structures of aglycones and/or the sugar residues. These include screening natural products, chemical synthesis of novel aglycones [16] , and genetic manipulation of anthracycline-producing bacteria [2, 17] .
Previously we reported the purification and characterisation of an anthracycline from Streptomyces olindensis ICB20 containing a β-rhodomycinone aglycone O-linked at each of C-7 and C-10 to trisaccharide chains comprising L-rhodosamine, 2-deoxy-L-fucose and L-rhodinose [18] . This compound was identified as cosmomycin D (CosD) which was originally isolated from Streptomyces cosmosus in the mid-1980s [19, 20] . In that early work, CosD was shown to induce differentiation in cultured Friend F5-5 leukemia (mouse) cells under conditions where doxorubicin, daunorubicin and aclacinomycin A had no measureable effect. This implies that the structural features of CosD favour a different set of intermolecular interactions in the cell. Since these initial observations there had been no further investigations of the properties of this compound. Our recent work reported the first investigations of the DNA-binding properties of CosD [18] . A preliminary survey of the binding of CosD to double-stranded (ds) 16 mer DNA using electrospray ionization mass spectrometry (ESI-MS) showed that 3-4 CosD molecules bound to the DNA compared with 4-5 for Dn. A gel mobility shift assay (using only one concentration of drug) showed that CosD decreased the mobility of plasmid DNA to a greater extent than Dx or Dn [18] . CosD on unwinding supercoiled plasmid DNA was investigated using agarose gels.
Materials and methods
All reagents were of the highest grade commercially available and MilliQ™ water was used in all experiments.
Oligonucleotides
Oligonucleotides ( Figure 2 ) were purchased from Geneworks (South Australia) as the trityloff derivatives and were dissolved in 10 mM ammonium acetate for purification using a Waters HPLC. Samples were loaded onto a C-18 octadecylsilyl column (8 x 100 mm, Waters Delta Pak Radial Pak Cartridge) equilibrated at 1 mL min -1 with 10 mM ammonium acetate and were eluted from the column using an acetonitrile gradient (0-60% over 30 min). The oligonucleotides free of sodium were freeze-dried using a Savant Speed-Vac and redissolved in 100 mM ammonium acetate, pH 7.5. The concentration of ssDNA was determined by measuring the absorbance at 260 nm and applying the molar extinction coefficients for the individual bases of 12010, 15200, 7050
and 8400 M -1 cm -1 for guanine, adenine, cytosine and thymine, respectively. Double-stranded DNA (to give 1 mM) was obtained by annealing the appropriate relative amounts of the complementary single strands in 100 mM ammonium acetate, pH 7.5, by heating to 90 °C for 15 min and allowing to cool slowly to room temperature.
Anthracyclines
Daunorubicin and doxorubicin were purchased from Sigma-Aldrich (St Louis, USA) and were used without further purification. Cosmomycin D from Streptomyces olindensis ICB20 was purified from methanol extracts of liquid cultures as previously described [18] . In some experiments, pure CosD was obtained from relatively crude culture extracts by dissolving the dried methanol extract in water, sonicating for 5 min and centrifuging in an Eppendorf microfuge (10,000 rpm, 4 °C, 15 min). The supernatant was frozen for 24 hours, thawed slowly to room temperature, and centrifuged as before. The freeze-dried supernatant was dissolved in water (50 mg/mL) and filtered using a 0.45 µm nylon syringe filter. The filtrate was purified by HPLC using a Jupiter C4 column (Phenomenex, 10 x 250 mm, 5 µm, 300 Å) equilibrated at 3 mL/min with 100 mM ammonium acetate, pH 7.5, and eluted using a 0-65% acetonitrile gradient over 65 min.
Cosmomycin D eluted at 35.2 min and was obtained as a red-purple powder after freeze-drying. All anthracycline stock solutions (1 mM for Dn and Dx and 0.5 mM for CosD) were prepared in 100 mM ammonium acetate, pH 7.5.
Preparation of anthracycline-DNA complexes
Equimolar ( 
Agarose gel electrophoresis
The plasmid DNA (pUC9) was grown and purified using a QIAGEN plasmid Maxi Kit, and its concentration was calculated from its absorption at 260 nm. The DNA (pUC9, 50 µg/ml) and drug (1 to 20 µM for Dn and CosD and 1 to 50 µM for Dx,) stock solutions were prepared in 50 mM ammonium acetate, pH 7. 
Mass spectrometry
Samples were analysed using a Waters Q-ToF Ultima ESI mass spectrometer equipped with a Zspray ionization source and a quadrupole mass analyzer with a m/z range of 32,000 (not necessary to have this m/z range for these experiments). Samples were injected to the mass spectrometer using a Harvard Model 22 syringe pump (Natick, MA, USA). All spectra were acquired using a MCP potential of 2100 V, RF lens energy of 70 V, and the cone and capillary voltages were 100 V and 2.5 kV, respectively. The source temperature was 80 °C and the desolvation gas flow was 300 L/hr at a temperature of 100 °C. Spectra were acquired in negative ion mode over the range m/z 500-4000 and typically 10 scans were summed to obtained a representative spectrum. In the nuclease digestion experiments, the cone voltage was set to 250 V, the source temperature to 60 °C, the desolvation gas temperature to 200 °C and typically 40 scans were summed to obtain a representative spectrum; all the other parameters were the same as above. The instrument was calibrated using a CsI solution (1 mg/mL) over the same m/z range. Tandem mass spectrometry experiments (MS/MS) were carried out under the same conditions with argon as the collision gas set to a pressure of 15 psi. The collision energy was varied form 0 to 28 V to establish a relationship between the amount of energy applied and the dissociation products observed. All experiments were repeated at least twice and the results were reproducible.
Results and Discussion

Agarose gel electrophoresis of anthracycline complexes with pUC9
Intercalators stack between base pairs of dsDNA, causing it to lengthen, unwinding the negative supercoil, and decreasing the mobility through agarose gels [21] . The migration of complexes of Dx, Dn and CosD with the plasmid pUC9 through agarose gels was investigated to compare the degree of unwinding induced by intercalation. Plasmid DNA was treated with a range of concentrations of the different anthracyclines and the mixtures were run on gels and stained using ethidium bromide. This is consistent with the positive charges on CosD (two tertiary amines) neutralizing negative charges on DNA as has been observed for other positively charged DNA-binding compounds [22] .
The two effects: DNA-unwinding and the effect of positive charge complicates calculation of an unwinding angle as a result of intercalation of CosD.
ESI-MS of anthracycline-DNA complexes
There are now many examples from our laboratory and others where non-covalent drug-DNA complexes have been detected and analysed by ESI-MS [24] [25] [26] [27] [28] [29] . These experiments are routine in our laboratory and others, and preliminary screening of drug-binding to previously prepared 16 mer DNA sequences can be carried out in approximately two hours. Figure 2 shows the DNA sequences While the rings of anthracyclines intercalate between DNA base pairs, the amino sugars bind in the minor groove of DNA [30] . There are no X-ray or NMR structures available for a CosD-DNA complex or for any anthracycline containing two trisaccharide chains. A structure of aclacinomycin bound to 6 mer dsDNA shows that its single trisaccharide chain also lies in the minor groove of the DNA [31] . It seems likely that the trisaccharide chains of CosD will also bind in the minor groove. ESI-MS experiments cannot directly comment on the structure of the DNA complexes detected. It is possible that some of the less abundant complexes may have been bound non-specifically, perhaps as a result of an electrostatic interaction between the positively charged drugs and the phosphodiester backbone of DNA. This possibility was minimized in these experiments by using a high salt concentration (100 mM) and low concentrations (µM) of analyte [32] .
In order to test that the CosD-DNA complexes were "specific", that is, resulted from intercalation between base pairs of dsDNA, the 10 mer sequence, F0AT, was modified by addition of single-stranded (ss) tails (poly dA of either 10 or 20 nucleotides in length; see Figure 2 for sequences). If double-stranded DNA is required for binding, and non-specific electrostatic-only interactions are minimal, then the maximum number of anthracycline molecules that bind to the DNA (binding profile) is expected to be unchanged when ssDNA tails are added to F0AT. Figure 5 shows the relative abundances of different anthracycline-DNA complexes (binding profiles) in different saturating mixtures of Dn, Dx or CosD with F0AT ( Figure 5A ), F10A1 ( Figure 5B ; a poly dA 10 tail was added to one of the strands of F0AT), F20A2 ( Figure 5C ; a poly dA 20 tail was added to one of the strands of F0AT), and F20A1A2 ( Figure 5D ; poly dA 20 tails were added to both strands of F0AT, giving a forked DNA structure). The predominant complex in the mixture of the 2CosD predominant in the saturating mixture with CosD (1:2.5). Since the F0AT sequence is six base pairs shorter than Rt1 (Figure 2) , it is expected that fewer anthracycline molecules will be able to bind as a result of steric hindrance. The results for Dn (3 bound as the major complex for F0AT compared with 4 for Rt1) and CosD (2 for F0AT compared with 3 for Rt1) are consistent with this.
The major feature of these binding profiles is that they were similar for all the sequences: the double-stranded F0AT, F0AT with single-strand extensions and the forked structure, supporting that the anthracyclines bound to the double-stranded region through intercalation.
Similar observations were made for Dx, but fewer Dx molecules bound to all the sequences containing F0AT than for Dn. This was not evident in the studies using the 16 mer sequence Rt1
where the binding profiles of Dn and Dx substantially overlapped ( Figure 4E ). This observation is consistent with a sequence specificity of Dx that is not exhibited by Dn. X-ray structures of Dn and Dx complexes with dsDNA have previously revealed structural differences that might account for the different clinical activities of these two drugs [8] .
Nuclease footprinting analysed by ESI-MS
Footprinting studies using nuclease and/or chemical digestion have been used to gain insight into the binding sites of anthracyclines on DNA [7, 33] . Typically, a plasmid fragment of several hundred base pairs is isolated, labelled, and mixed with the anthracycline prior to addition of Dnase I. The fragments produced are isolated by precipitation and analysed using denaturing polyacrylamide gels. In this way, it has previously been demonstrated that anthracyclines with a greater number of sugar residues have a greater footprint on DNA [7] . In the current work, a simple, rapid method was used to screen the footprint of Dn, Dx and CosD on the 16 mer Rt1 DNA. There has been one other DNA footprinting study of an anthracycline with two trisaccharide chains. This was ditrisarubicin, in which the terminal two sugars are fused (Figure 1 ). In these experiments, the DNA was a 375 base pair fragment of pBR322 DNA [7] . This work also showed that ditrisarubicin protected a greater number of DNA base pairs from chemical and Dnase I cleavage than the less extensively glycosylated daunorubicin.
After annealing the commercially available DNA strands, an entire nuclease digestion experiment analysed by ESI-MS could be completed in an hour and using only 2 picograms of CosD. The experimental procedure could be modified in several ways to provide further information, and we are currently carrying out experiments to standardize these methods. For example, analysis of the digestion products at early time points or using low nuclease concentrations will provide information about where the drug molecules are bound on the sequence.
Stability of anthracycline-DNA complexes judged by tandem mass spectrometry
In tandem mass spectrometry experiments (ESI-MS/MS), an ion is selected (in the quadrupole in the case of a quadrupole time-of-flight, Q-ToF, instrument) and accelerated through a collision cell containing a low pressure of inert gas such as argon. Complexes dissociate (or covalent bonds are broken) when the kinetic energy is converted to internal energy as a result of collisions with the argon. The products of the dissociated complex are then analyzed in the ToF mass analyzer. The more stable the complex, the greater the collision energy that needs to be applied to dissociate the complex for a given dissociation pathway. The stabilities of Dn-and DxdsDNA complexes have previously been compared in this way [28, 29] .
In the current work the ESI-MS/MS dissociation behaviors of Dn-and Dx-Rt1 complexes were compared with results previously reported in the literature [28, 29] with other studies using different DNA sequences (12-and 14 mer sequences also with terminal guanine residues) [28, 29] .
For a given collision energy and for all complexes, the greater stability of the CosD-Rt1 complexes was evident in that a higher energy was required to dissociate CosD from the DNA. To illustrate this, Figure 7 shows negative ion ESI-MS/MS spectra (collision energy, 10 V), of the ions carrying 5 negative charges of Rt1, Rt1 + 2 Dn, Rt1 + 2 Dx and Rt1 + 2CosD. The precursor ion (the ion selected for dissociation in the collision cell) is designated by an arrow in each spectrum.
Under these conditions, Rt1 was not separated to single strands, but an ion of low abundance corresponding to the loss of a guanine from Rt1 was evident ( Figure 7A ). For Rt1 + 2Dn (B) and Rt1 + 2Dx (C), the products were Rt1, Rt1 +1Anthracycline and the corresponding complexes that had lost guanine. The complex with Dx was somewhat more stable than that with Dn as evidenced by the greater abundance of the product ions in the ESI-MS/MS spectrum for Rt1 + 1Dn ( Figure   7B ) compared with Rt1 + 1Dx ( Figure 7C ), in agreement with other work [29] . This observation has been explained in terms of an increase in activation enthalpy for DNA complexes with Dx compared with Dn as a consequence of the extra H-bond that may be present in complexes with Dx [29, 6] . At this collision energy, and at all collision energies tested (up to 24 V), no CosD molecules dissociated from the DNA. The results were the same for Rt1 complexes with 3 molecules of each of the anthracyclines. At high collision energies (26 V), it was possible to dissociate all of the Dn and Dx from the DNA.
The complexes Rt1 + xCosD carrying six negative charges were also more stable than the corresponding ions for complexes with Dn and Dx. In contrast to the complexes carrying five negative charges, it was possible to dissociate one CosD from Rt1 + 3CosD giving Rt1 + 2CosD
carrying only five charges. This tightly bound complex resisted further loss of CosD molecules as the collision energy was increased to 24 V; it was not possible to apply higher collision energies
and maintain the quality of the mass spectra. Similar behavior has been observed for the dissociation of actinomycin D from 12 mer dsDNA using a Q-ToF mass spectrometer similar to the one used in the current experiments. This intercalator contains two bulky cyclic peptides that lie in the minor groove [29] . A complete and detailed study of the dissociation of CosD-DNA complexes carrying different numbers of charges, ion mobility experiments to examine the distribution of conformations of the complexes, and a discussion of the possible explanations for the differences in stabilities is to be reported elsewhere. 
Conclusions
